News & Updates

A 71-year-old woman, previously well, presented with a 3-month history of bilat­eral lower-limb rash. Initial blood test on 22 December 2023 showed leukocytosis with white blood cell (WBC) count 17.8 x 10⁹/L, haemoglobin 10.3 g/dL and plate­lets 172 x 10⁹/L. Peripheral blood analysis found 14 percent blast cells and marked monocytosis (15 percent). She was ad­mitted for further evaluation.

Increased prostate volume in patients with low-grade prostate cancer on active surveillance appears to contribute to reduced risks of grade progression (GP) and receipt of definitive prostate cancer treatment, suggests a study.

In patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), allogeneic haematopoietic stem cell transplantation (HSCT) after blinatumomab is feasible and potentially safe, according to data from a nationwide registry in Japan.

First-line (1L) blinatumomab + ponatinib improves patient-reported outcomes (PROs), including fatigue and health-related quality of life (HRQoL), vs imatinib + chemotherapy in adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia (ALL), results of the phase III GIMEMA ALL2820 trial have shown.

Infants with KMT2A-rearranged acute lymphoblastic leukaemia (ALL) – a dire disease with poor prognosis despite treatment intensification under the latest protocols – are found to have improved 4-year disease-free survival (DFS) and overall survival (OS) with the addition of blinatumomab to standard chemotherapy.

Replacing two cycles of highly toxic, high-dose combination chemotherapy with two cycles of blinatumomab as first-line (1L) treatment significantly improves outcomes including 4-year event-free survival (EFS) and reduces adverse events (AEs) in paediatric patients with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), results of the phase III AIEOP-BFM 2017 trial have shown.

In patients with locally advanced or metastatic urothelial cancer, enfortumab vedotin (EV)-induced cutaneous adverse events (cAEs) are associated with improved survival outcomes, according to a retrospective study.

Letermovir prophylaxis falls short of reducing medication regimen complexity index (MRCI) over time in patients who underwent allogeneic haematopoietic stem cell transplantation (allo-HCT), according to a study.

Patients with ovarian cancer are no strangers to several drug therapy problems (DTPs), particularly adverse drug reactions, suggests a study.

The survival benefit associated with the use of statins in adults treated for colorectal cancer (CRC) is only modest at best, according to a target trial emulation.